41 results on '"Tebas, Pablo"'
Search Results
2. The Penn Medicine COVID-19 Therapeutics Committee—Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency
3. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)
4. Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2
5. SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
6. 578. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
7. 571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
8. 532. Establishing a SARS-CoV-2 Monoclonal Antibody Infusion Clinic: Early Trends in Outcomes and Disparities
9. Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization
10. Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy
11. Clinical Outcomes of Clofazimine Use for Rapidly Growing Mycobacterial Infections
12. 318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
13. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
14. 1028. Synergizing Infectious Diseases and Substance Use Treatment to Improve the Outcomes of Endocarditis in People Who Inject Drugs at a Large Academic Hospital
15. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies
16. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus–Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy
17. The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk
18. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy
19. ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection
20. Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation
21. Renal and Bone Outcomes Among HIV-Infected Patients Exposed to EFV/TDF/FTC Compared With Other Tenofovir Disoproxil Fumarate–Containing Antiretroviral Regimens: Findings From the Veterans Health Administration (VHA)
22. Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women
23. Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) in Treatment-Experienced HIV-1 Infected Adults (NCT01968551)
24. Seroprotection of HIV-Infected Subjects After Influenza A(H1N1) Vaccination Is Directly Associated With Baseline Frequency of Naive T Cells
25. 1602Impact of IGF-1 and Sex Steroids on Bone Health in HIV- and HCV-Infected US Male Veterans
26. 645Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women
27. Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis
28. Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration
29. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
30. Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers
31. Is It Time to Rethink the Expanded‐Access Programs for HIV Infection?
32. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations
33. Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV‐1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
34. Reply to Rojo and Ramos and to Vignolo et al.
35. Real-Time Nucleic Acid Sequence–Based Amplification Assay to Quantify Changes in Mitochondrial DNA Concentrations in Cell Cultures and Blood Cells from HIV-Infected Patients Receiving Antiviral Therapy
36. Bone Disease and HIV Infection
37. Emerging Bone Problems in Patients Infected with Human Immunodeficiency Virus
38. Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected Individuals
39. Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Individuals for Whom Interferon‐α and Lamivudine Therapy Have Failed
40. Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4+T Cell Decline in Human Immunodeficiency Virus–Infected Patients: Implications for Intermittent Therapeutic Strategies
41. Notes Progressive Multifocal Leukoencephalopathy in Patients with AIDS Receiving Highly Active Antiretroviral Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.